admin, Author at PsyNews.com

Home Authors Posts by admin

2176 POSTS 0 COMMENTS

https://psynews.com

COMPASS Pathways announces publication of positive data from treatment-resistant depression phase...

FILAMENT HEALTH ANNOUNCES CHANGE OF AUDITOR

Algernon Pharmaceuticals Announces Private Placement and Issuance of Shares in Connection...

Reunion Neuroscience Inc. Obtains Final Court Order for Proposed Plan of Arrangement

Maximizing Mushrooms: How to Make a Little Psilocybin Go a Long...

PT423 – The Watts Connectedness Scale, The Importance of Elders, and...

Reunion Neuroscience Inc. Shareholders Approve Proposed Plan of Arrangement

Opinion paper calls for clarity on the definition of “psychedelic-assisted therapy”...

BetterLife Highlights American College of Physicians’ Updated Guidelines for Treating Depression...

Dr. Fatima Cody Stanford, Associate Professor of Medicine and Pediatrics at...

1...565758...218 Page 57 of 218

EDITOR PICKS

‘No Prejudice, No Hype’: Florence Butlen-Ducuing on Europe’s Psychedelic Renaissance

August 2025 Psychedelic Patent Update

Unpacking FDA’s MDMA Rejection Letter and the Road Ahead for Lykos

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

admin